Effects of short-term sitagliptin treatment on immune parameters in healthy individuals, a randomized placebo-controlled study

Clinical and Experimental Immunology

Volumn 174, Issue 1, 2013, Pages 120-128

  Price, J D ^a   Linder, G ^a   Li, W P ^a   Zimmermann, B ^a   Rother, K I ^a   Malek, R ^a   Alattar, M ^a   Tarbell, K V ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Cytokine; Dipeptidyl peptidase 4; GLP 1; Immune function

Indexed keywords

CD3 ANTIGEN; CHEMOKINE; DIPEPTIDYL PEPTIDASE IV; LIPOPOLYSACCHARIDE; PLACEBO; SITAGLIPTIN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; CELL POPULATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; IMMUNOASSAY; IMMUNOMODULATION; LEUKOCYTE; NORMAL HUMAN; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

CYTOKINE; DIPEPTIDYL-PEPTIDASE 4; GLP-1; IMMUNE FUNCTION;

DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DOWN-REGULATION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; IMMUNOMODULATION; OUTCOME ASSESSMENT (HEALTH CARE); PYRAZINES; T-LYMPHOCYTE SUBSETS; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; TRIAZOLES; UP-REGULATION;

EID: 84883609473     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12144     Document Type: Article

References (28)

1. Herman GA, Stevens C, Van Dyck K etal. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005; 78:675-688.
2. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298:194-206.
3. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag 2008; 4:753-768.
4. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008; (2):CD006739.
5. Nishioka T, Shinohara M, Tanimoto N, Kumagai C, Hashimoto K. Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis. Dermatology 2012; 224:20-21.
6. Suen CS, Burn P. The potential of incretin-based therapies in type 1 diabetes. Drug Discov Today 2012; 17:89-95.
7. Fox DA, Hussey RE, Fitzgerald KA etal. Ta1, a novel 105KD human T cell activation antigen defined by a monoclonal antibody. J Immunol 1984; 133:1250-1256.
8. Ishii T, Ohnuma K, Murakami A etal. CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO. Proc Natl Acad Sci USA 2001; 98:12138-12143.
9. Yazbeck R, Howarth GS, Abbott CA. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci 2009; 30:600-607.
10. Ohnuma K, Munakata Y, Ishii T etal. Soluble CD26/dipeptidyl peptidase IV induces T cell proliferation through CD86 up-regulation on APCs. J Immunol 2001; 167:6745-6755.
11. Martinez-Navio JM, Casanova V, Pacheco R etal. Adenosine deaminase potentiates the generation of effector, memory, and regulatory CD4+ T cells. J Leukoc Biol 2011; 89:127-136.
12. Kirby M, Yu DM, O'Connor S, Gorrell MD. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci 2010; 118:31-41.
13. Yu DM, Slaitini L, Gysbers V etal. Soluble CD26/dipeptidyl peptidase IV enhances human lymphocyte proliferation in vitro independent of dipeptidyl peptidase enzyme activity and adenosine deaminase binding. Scand J Immunol 2011; 73:102-111.
14. Shah Z, Kampfrath T, Deiuliis JA etal. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011; 124:2338-2349.
15. Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003; 40:209-294.
16. Iwata S, Yamaguchi N, Munakata Y etal. CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response. Int Immunol 1999; 11:417-426.
17. Campbell TB, Hangoc G, Liu Y, Pollok K, Broxmeyer HE. Inhibition of CD26 in human cord blood CD34+ cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice. Stem Cells Dev 2007; 16:347-354.
18. Tian L, Gao J, Hao J etal. Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor. Endocrinology 2010; 151:3049-3060.
19. Kim SJ, Nian C, Doudet DJ, McIntosh CH. Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes 2009; 58:641-651.
20. Hagihara M, Ohhashi M, Nagatsu T. Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in mice with lupus erythematosus-like syndrome and in patients with lupus erythematosus and rheumatoid arthritis. Clin Chem 1987; 33:1463-1465.
21. Krakauer M, Sorensen PS, Sellebjerg F. CD4(+) memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosis. J Neuroimmunol 2006; 181:157-164.
22. Ellingsen T, Hornung N, Moller BK, Hjelm-Poulsen J, Stengaard-Pedersen K. In active chronic rheumatoid arthritis, dipeptidyl peptidase IV density is increased on monocytes and CD4(+) T lymphocytes. Scand J Immunol 2007; 66:451-457.
23. White PC, Chamberlain-Shea H, de la Morena MT. Sitagliptin treatment of patients with type 2 diabetes does not affect CD4+ T-cell activation. J Diabetes Complications 2010; 24:209-213.
24. Reinhold D, Bank U, Buhling F etal. A detailed protocol for the measurement of TGF-beta1 in human blood samples. J Immunol Methods 1997; 209:203-206.
25. de Meester I, Scharpe S, Vanham G etal. Antibody binding profile of purified and cell-bound CD26. Designation of BT5/9 and TA5.9 to the CD26 cluster. Immunobiology 1993; 188:145-158.
26. Ram M, Sherer Y, Shoenfeld Y. Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol 2006; 26:299-307.
27. Pilla E, Moller U, Sauer G, Mattiroli F, Melchior F, Geiss-Friedlander R. A novel SUMO1-specific interacting motif in dipeptidyl peptidase 9 (DPP9) that is important for enzymatic regulation. J Biol Chem 2012; 287:44320-44329.
28. Matteucci E, Giampietro O. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. Curr Med Chem 2009; 16:2943-2951.